Granules India Ltd. 21 st July, 2012
|
|
- Clare King
- 6 years ago
- Views:
Transcription
1 Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Granules India Ltd. 21 st July, 2012 CMP Target Price Rs Rs Granules India is among the leading global manufacturer of highvolume APIs including Paracetamol, Ibuprofen, Metformin and Guaifenesin. Additionally, Granules pioneered the concept of commercialising PFIs and is the world s largest PFI facility. BSE Code NSE Code GRANULES Market Cap (Rs Mn) Week High/Low /55.00 Industry Pharmaceuticals Face Value Rs Shares O/S EPS Book Value P/E P/B 1.22 Shareholding Pattern The Indian pharmaceutical industry grew at a CAGR of 14% in the five years leading to FY12; Granules revenues grew at a 28% CAGR during the period. GIL continued to strengthen its position in the rapidly growing market and is aiming at achieving productivity gains, growth in volumes, sustained margins and neutralising cost increases. The company has registered smart numbers for the quarter ending March The revenue from operations has increased by 56.89% at Rs crore for quarter under review as compared to Rs crore for the quarter ended March 31, 2011 translating in operating profit of Rs crore; up by 46.37% y-oy. A comparatively tremendous net profit growth of 85.71% to Rs was reported for the Q4FY12 compared to Rs.8.82 crore of same quarter previous year. Growth in revenue and profits was driven by higher growth in the finished dosage segment. EPS almost doubled at Rs.8.15 y-o-y. GIL offers all three components of the pharmaceutical value chain which gives the customers flexibility and choice. It manufactures PFIs (strategically backward integrated through the in-house manufacture of APIs) to finished dosages (tablets in bulk). Valuation Research Analyst: Vineeta Mahnot research@hemonline.com With efficient manufacturing value chain, increasing utilization, complete vertical integration and capacity expansion GIL s revenue visibility looks strong. We believe GIL is trading at an attractive valuation at 7.17x and 5.2x of FY13EPS of Rs and FY14EPS of Rs We initiate a BUY on the stock with a target price of Rs.200 (appreciation of about 34%) with the short to medium term investment horizon. For Private Circulation Only 1 Hem Research
2 Business Details Granules India (GIL) was incorporated as Private Limited Company in 1991 and was converted into a Public Limited Company in It is a fast growing pharmaceutical manufacturing company with world class facilities partnering with market leaders to offer pharmaceutical products and services and is committed to manufacturing excellence, quality and customer service. Granules India (GIL) has a long history as a producer of active pharmaceutical ingredients (API's) and pharmaceutical formulation intermediates (PFIs) with complete vertical integration for quality conscious customers in the regulated and semi-regulated markets. They support customers with unique value, extensive product range and a global network of associates. The Company is headquartered in Hyderabad with sales offices in the U.S., the U.K., Colombia and China. The Company services the growing needs of more than 300 customers across 60 nations. GIL is a fully vertically integrated pharmaceutical manufacturing company with three core lines: Active Pharmaceutical Ingredients (APIs) Granules has 3 factories manufacturing APIs. It is among the top global manufacturers of Paracetamol and Ibuprofen. Pharmaceutical Formulation Intermediates (PFIs) Granules pioneered the concept of PFIs and currently has 2 factories manufacturing single and multiple - active PFIs. Its Gagillapur facility has an industry-leading 6 MT single batch size. Finished Dosages (FDs) Granules has a dedicated FD plant at the Gagillapur facility. Its plant has the capacity to produce 6 billion tablets annually and is scalable up to 18 billion tablets. The facility has received approval from U.S.FDA, Infarmed and the Australian TGA. For Private Circulation Only 2 Hem Research
3 Strong industry growth India's pharmaceutical sector is gaining its position as a global leader. The domestic pharmaceutical market (IPM) grew 21.9 per cent to record sales of Rs 5,369 crore (US$ 1.01 billion) in March 2012, as compared to the previous year, according to an analysis by a market research firm, All India Organisation of Chemists and Druggists (AIOCD) AWACS. The drugs and pharmaceuticals sector attracted foreign direct investments (FDI) worth US$ 9, million between April 2000 to February 2012, according to the latest data published by Department of Industrial Policy and Promotion (DIPP). India tops the world in exporting generic medicines worth US$ 11 billion. Currently, the Indian pharmaceutical industry is one of the world's largest and most developed. India has world renowned capacity in producing low cost, high quality bulk and generic drugs. Export-import growth Export Import Rs. Crores (% chg.) Rs. Crores (% chg.) , , , , , , , , , , , , E 60, , E 73, , E 78, , Drug exports from India in rupee terms, were higher by 32.6 per cent to Rs.56,842 crore compared to the year ago period. A weak rupee and healthy demand for generic drugs contributed to the growth. Drug exports to the US rose by 39.1 per cent during April 2011-February The US is the largest market for Indian generic drug exports. Exports to UK and Germany grew by 32.3 per cent and 34.5 per cent, respectively. Exports to Russia and Brazil were higher by 28.9 per cent and 28.6 per cent, respectively. In rupee terms, imports were higher by 22.5 per cent to Rs.12,937.6 crore during April 2011-February Indian pharma industry is the largest exporter of generic drugs. And capitalising on their expertise in process engineering and low cost advantage, the pharma industry continues to achieve a larger share in the pie of global generics market. For achieving this, the domestic companies are also diversifying their product portfolios, becoming vertically integrated across the manufacturing process and expanding their geographic presence especially in the emerging markets. CMIE expects drug exports to have grown by 28.5 per cent to Rs.60,865 crore in and Rs.73,925 crore in Exports are likely to grow by 21.5 per cent during the year. For Private Circulation Only 3 Hem Research
4 The global pharmaceutical sector will witness the biggest patent-expiration wave in The peak of the patent expiration wave in 2011 and 2012 will witness over USD40 bn of branded sales going generic in the world s largest pharma market. Around USD 80 billion worth of drugs are expected to go off-patent in Drugs worth USD125 bn are expected to go off-patent between 2011and 2016 in the U.S. against only USD71 bn during (IMS Data). Developed countries like the US, UK and Japan are moving from branded drugs to unbranded or generic drugs. The rising healthcare cost has prompted the government of these companies to turn to the generic mode to curtail costs. In order to take advantage of the patent-cliff, domestic generic companies are scaling up their R&D facilities. In order to encourage R&D, the government extended investment linked benefits to the drug industry in the Union Budget On an average, R&D expenditure accounts for six per cent of the pharma industry s sales. In , four R&D projects entailing a total cost of Rs.420 crore were commissioned. In the June 2012 quarter, two R&D projects were commissioned. Biocon commissioned its R&D project at Pune at a cost of Rs.200 crore. Granules India commissioned its R&D centre project at Pune. Another four R&D project with a total investment of Rs crore are likely to commission during During July 2012-March 2013, 53 projects worth over Rs.5,515.4 crore are scheduled to commission. In , 19 projects worth over Rs.3,450.5 crore are scheduled to commission. In order to harness the full potential of the Comprehensive Free Trade Agreement with Japan, India is likely to press the former for further opening of the pharmaceutical sector. This would help the domestic industry to leverage Comprehensive Economic Partnership Agreement (CEPA) and increase its share in the Japanese market. Indian pharmaceutical industry would gain significantly from the pact as Japan, the world's second largest market, had agreed to cut duties on imports of Indian generic drugs The Ministry of Commerce has proposed an ambitious Strategy Plan to double pharmaceutical exports from US$ 10.4 billion in to US$ 25 billion by The Government has also planned a 'Pharma India' brand promotion action plan spanning over a three-year period to give an impetus to generic exports. On the back of increasing middle-class population base, improvements in medical infrastructure and the establishment of IP rights, the Indian pharma industry is estimated to grow manifolds. Strong growth in exports will boost the sales growth of the industry. The domestic demand is also expected to remain healthy. Hence, net sales of the industry is expected to grow by 16.8 per cent in A slower 3.1 per cent growth in other expenses will help to improve the core operating performance which is expected to penetrate to the net levels. The PAT is likely to grow by a robust 52.3 per cent during the year. Profit margins are likely to expand. For Private Circulation Only 4 Hem Research
5 Efficient business model While most pharmaceutical manufacturers focus on one product vertical-active pharmaceutical ingredients and Finished Dosages (APIs or FDs); Granules cover all three aspects APIs, PFIs and FDs, which enables the Company to add value throughout the manufacturing value chain. The company s FD facility is among the world s largest singlesite capacity facilities; while its API facilities are among the premier facilities for quality-conscious customers. The company has diversified its sales by reducing contribution from Paracetamol to less than 50% in FY12 from 70% in FY08. It has increased sales of higher value products that offer stronger margins like Metformin, Ibuprofen and Guaifenesin. For Private Circulation Only 5 Hem Research
6 Capacity expansion In financial year , the Company commenced work on an expansion at its Gagillapur facility. The expansion involved a capacity expansion in the PFI and Finished Dosage facilities. Granules moved up the value chain from APIs to PFIs and Finished Dosages, which it expects to continue going ahead too. Several projects to increase API capacity were implemented during FY12, with many of the projects finishing in late Q4FY12. The full benefits of these projects will be realized in FY13; API capacities increased 18% over the past three year. The PFI facility was expanded with the addition of two modules: Module-C, a state-of-the-art module with a capacity of 8,400 tons and Module-D, a facility with a capacity of 1,200 tons. In early FY13, Granules will complete expansion plans that will more than double our PFI capacity to 18,000 tonnes while tripling its FD capacity to 18 billion doses. The expansion will strengthen GIL s position as the largest PFI producer and will give it one of the largest single-site finished dosage facilities. GIL has the advantage of building the capacities in the same premises as regulatory approvals are already there. GIL expects FY13 to be a breakout year for the company with all the new capacities coming up. The company has a strong order book and expects healthy capacity utilization in FY13 which would result in increased margins. Joint venture with Ajinomoto Omnichem to reap benefits soon Granules entered into a (50:50) joint venture with Ajinomoto Omnichem, a leading CRAMs manufacturer and a Belgium based Company during the financial year The JV will manufacture pharmaceutical intermediates and APIs in a greenfield facility in Visakhapatnam (AP) and mainly focus on high-value, low-volume APIs for the regulated markets. The JV is focued on high-value APIs in several therapeutic sectors including oncology, cardiovascular and central nervous system (CNS). In FY13 the JV will commence operations but revenues will start kicking in FY14-FY15. The JV will be benefitted with the technological excellence and operating efficiency of Granules together with wide customer base and extensive product portfolio of Omnichem. For Private Circulation Only 6 Hem Research
7 Strong financial performance Granules has come out with excellent numbers for the financial year ending March Its revenues grew by sharp 38% at Rs.654 crore from Rs.475 crore; it continued the trend of outperforming the industry. About 50% of the Company s revenues were derived from customer relationships longer than five years; proportion of revenues from fixed contracts increased from 23% in FY10 to 48% in FY12. More than 68% of the revenues in FY12 came from regulated markets. Operating profit stood at Rs.79 crore compared to Rs.57 crore in the previous financial year registering a growth of 39% in the current financial year. The Company registered growth on all fronts. Net profit skyrocketed 43% at Rs crore from Rs crore. EPS for the financial year ended March 2012 stood at Rs API revenues increased 20% from Rs.151 Cr. in FY11 to Rs.181 Cr. Paracetamol output increased from 800 TPM to 1,000 TPM within two quarters with relevant de-bottlenecking and minimal capital expenditure. Metformin production increased from 100 TPM in FY11 to 150 TPM and Guaifenesin production increased from 60 TPM in FY11 to 100 TPM through process improvements. PFIs revenues increased 27% from Rs.155 crore in FY11 to Rs.197 crore supported by increased production volumes and improved realizations (effect of price increases). During the year, GIL commissioned Module D (1,200 TPA) at Gagillapur. Revenues from Finished Dosages climbed sharply by 83% from Rs.101 crore to Rs.185 crore in FY12. During the year, the company received an approval for its Naproxen Sodium 220 mg ANDA and also filed ANDA with USFDA for Ibuprofen Rx. For Private Circulation Only 7 Hem Research
8 Consolidated Profit & Loss Account Rs. Crore Particulars FY10 FY11 FY12 FY13E FY14E Net sales Growth 3.06% 37.62% 30.00% 25.00% Expenditure EBITDA Growth -7.52% 39.29% 34.29% 27.00% EBITDA margin 13.32% 11.96% 12.10% 12.50% 12.70% Other income Depreciation & Amortization EBIT EBIT margin 11.96% 8.15% 9.03% 9.60% 10.05% Interest PBT Tax PAT Minority interest/share of JV/Associates Adjusted PAT Growth (31.22) Net Profit margins Extraordinary item Reported PAT Equity Capital Res. & Surplus Equity Shares EPS Ratios Particulars FY10 FY11 FY12 FY13E FY14E Return on Equity Return on Capital employed Debt/Equity Asset turnover Current Ratio Book value per share For Private Circulation Only 8 Hem Research
9 Balance Sheet Rs. Crore Particulars FY10 FY11 FY12 FY13E FY14E Share Capital Reserves & Surplus Shareholders funds Borrowings Deferred tax Liability Sources of funds Gross block Accumulated Depreciation Net block Capital work in progress Investments Projects in progress Inventories Sundry debtors Cash and bank balance Other current assets Loans and advances Total current assets Deferred tax asset Current liabilities and provisions Net current assets Misc exp Uses of funds For Private Circulation Only 9 Hem Research
10 Consolidated Quarterly Financial Highlights Rs. Crore Particulars Q4FY12 Q4FY11 Q3FY12 YoY% QoQ% Revenues Expenditures Operating Profit Net Profit OPM% (98bps) 16bps NPM % bps 441bps EPS Past Price movement of the stock For Private Circulation Only 10 Hem Research
11 HEM SECURITIES LIMITED MEMBER-BSE,CDSL, SEBI REGISTERED CATEGORY I MERCHANT BANKER MUMBAI OFFICE: 14/15, KHATAU BLDG., IST FLOOR, 40, BANK STREET, FORT, MUMBAI PHONE FAX JAIPUR OFFICE: , JAIPUR TOWERS, M I ROAD, JAIPUR PHONE FAX GROUP COMPANIES HEM FINLEASE PRIVATE LIMITED MEMBER-NSE HEM MULTI COMMODITIES PRIVATE LIMITED MEMBER-NCDEX, MCX HEM FINANCIAL SERVICES LIMITED NBFC REGISTERED WITH RBI For Private Circulation Only 11 Hem Research
12 Disclaimer & Disclosure: This document is prepared for our clients only, on the basis of publicly available information and other sources believed to be reliable. Whilst we are not soliciting any action based on this information, all care has been taken to ensure that the facts are accurate, fair and reasonable. This information is not intended as an offer or solicitation for the purchase or sell of any financial instrument and at any point should not be considered as an investment advise. Reader is requested to rely on his own decision and may take independent professional advise before investing. Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited, Directors and any of its employees shall not be responsible for the content. The person accessing this information specifically agrees to exempt Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and further agrees to hold Hem Securities Limited, Hem Finlease Private Limited, Hem Multi Commodities Pvt. Limited or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The companies and its affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material may from time to time, have long or short positions in, and buy or sell the securities there of, company (ies) mentioned here in and the same have acted upon or used the information prior to, or immediately following the publication. Disclosure of Interest Statement Company Name 1. Analyst Ownership of the Stock No 2. Hem & its Group Company Ownership of the Stock No 3. Hem & its Group Companies Director Ownership of the Stock No 4. Broking relationship with company covered No Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. For Private Circulation Only 12 Hem Research
R.S. Software (India) Ltd. 11 th August, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY R.S. Software (India) Ltd. 11 th August, 2014 BUY CMP Rs.430.00 Target Price Rs.600.00 BSE Code 517447 NSE Code RSSOFTWARE Market Cap (Rs
More informationVa Tech Wabag Ltd. 11 th March, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Va Tech Wabag Ltd. 11 th March, 2014 BUY CMP Target Price Rs.691.30 Rs.870.00 VA Tech Wabag is Indian multinational player technology focused
More informationNIIT Technologies Ltd. 15 th February, 2016 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY NIIT Technologies Ltd. 15 th February, 2016 BUY CMP Target Price Rs.500.95 Rs.645.00 BSE Code 532541 Market Cap (Rs Cr.) 3065.81 52 Week
More informationIdea Cellular Ltd. 19 th January, 2015 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Idea Cellular Ltd. 19 th January, 2015 BUY CMP Target Price Rs.155.20 Rs.210.00 BSE Code 532822 Market Cap (Rs Cr.) 55,832.96 52 Week High/Low
More informationMunjal Showa Ltd 30 th May, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Munjal Showa Ltd 30 th May, 2012 CMP Target Price Rs.79.00 Rs.100.00 Munjal Showa Limited in Hero Group's joint venture with Showa Corporation,
More informationTech Mahindra Ltd 21 st September, 2013 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Tech Mahindra Ltd 21 st September, 2013 BUY CMP Target Price Rs.1298.60 Rs.1650.00 Tech Mahindra is a global systems integrator and business
More informationIPCA Laboratories Ltd 26 th August, 2013 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY IPCA Laboratories Ltd 26 th August, 2013 BUY CMP(As on 24/8/13) Rs.623.30 Target Price Rs.780.00 BSE Code 524494 NSE Code IPCALAB Market
More informationCamlin Fine Sciences Ltd. 27 th June, 2015 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Camlin Fine Sciences Ltd. 27 th June, 2015 BUY CMP Target Price Rs.111.85 Rs.145.00 Camlin Fine Sciences is one of the India's leading
More informationV-Guard Industries Ltd 9 th June, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY V-Guard Industries Ltd 9 th June, 2012 CMP Rs.215.00 The V-Guard Group has emerged as one of the most trusted brand in India. VGIL plans
More informationPidilite Industries Ltd 10 th September, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Pidilite Industries Ltd 10 th September, 2012 CMP(as on 8/9/2012) Target Price Rs.200.50 Rs.260.00 Pidilite Industries Ltd. has been a
More informationGabriel India Ltd. 4 th November, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Gabriel India Ltd. 4 th November, 2014 BUY CMP(As on 3/11/2014) Rs.83.40 Target Price Rs.115.00 BSE Code 505714 NSE Code GABRIEL Market
More informationAlembic Pharmaceuticals Ltd 25 th September, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Alembic Pharmaceuticals Ltd 25 th September, 2012 CMP Target Price Rs.70.85 Rs.90.00 Alembic Pharma continues to maintain its market share
More informationCeat Ltd 1 st June, 2013 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Ceat Ltd 1 st June, 2013 BUY CMP Target Price Rs.107.75 Rs.140.00 Ceat is India s leading tyre company with over 50 years of presence.
More informationDCB Bank Ltd. 18 th August, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY DCB Bank Ltd. 18 th August, 2014 BUY CMP Rs.81.40 Target Price Rs.120.00 BSE Code 532772 NSE Code DCBBANK Market Cap (Rs Cr.) 2040.24 52
More informationMadras Cements Ltd 9 th October, 2012 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Madras Cements Ltd 9 th October, 2012 BUY CMP Target Price Rs.186.35 Rs.240.00 Madras Cements Ltd is the flagship company of the Ramco
More informationMinda Corporation Ltd. 29 th December, 2015 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Minda Corporation Ltd. 29 th December, 2015 BUY CMP Rs.89.40 Target Price Rs.120.00 BSE Code 538962 Market Cap (Rs Cr.) 1871.14 52 Week
More informationGateway Distriparks Ltd 1 st July, 2011 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Gateway Distriparks Ltd 1 st July, 2011 BUY CMP Rs 126.75 Target Price Rs 170.00 BSE Code 532622 NSE Code GDL Market Cap (Rs Mn) 13699.51
More informationGlenmark Pharmaceuticals Ltd 23 rd May, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Glenmark Pharmaceuticals Ltd 23 rd May, 2012 CMP(As on 22/5/2012) Rs.357.00 Target Price Rs 450.00 As per ORG IMS MAT March 2012 data,
More informationBalaji Amines Ltd 22/11/2017 BUY
BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY MERCHANT BANKING Balaji Amines Ltd 22/11/2017 BUY CMP Rs. 600.75 Target Price Rs 780.00 BSE Code 530999 NSE Code BALAMINES Market Cap (Rs crore) Rs.1946.43
More informationSteel Strips Wheels Ltd. 6 th August, 2016 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Steel Strips Wheels Ltd. 6 th August, 2016 BUY CMP Rs.511.80 Target Price Rs.640.00 BSE Code 513262 Market Cap (Rs Cr.) 794.42 52 Week
More informationCarborundum Universal Ltd 18 th July, 2011 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Carborundum Universal Ltd 18 th July, 2011 BUY CMP Rs 302.00 Target Price Rs 360.00 Large capacity expansions and major business acquisitions,
More informationIPO Report ICICI SECURITIES LTD SUBSCRIBE. Valuation. IPO Details. Research Analyst : Astha Jain
IPO Report ICICI SECURITIES LTD SUBSCRIBE IPO Details Issue Date 22 nd Mar-26 th Mar 2018 Price Band 519-520/Share Bid Lot 28 & in multiplethereof Face Value Rs 5/Share Listing BSE, NSE Offer For Sale
More informationSUBSCRIBE. IPO Report HDFC ASSET MANAGEMENT COMPANY LTD. IPO Details. Research Analyst : Astha Jain
IPO Report HDFC ASSET MANAGEMENT COMPANY LTD SUBSCRIBE IPO Details Issue Date 25 th July-27 th July 2018 Price Band 1095-1100/Share Bid Lot 13 & in multiplethereof Face Value Rs 5/Share Listing BSE, NSE
More informationMargin (%) PAT (Rs cr)
4 Recommendation HOLD Reiterating positive outlook CMP (27/7/2015) Rs. 115 Target Price Rs. 125 Sector Stock Details Pharmaceuticals BSE Code 532482 NSE Code Bloomberg Code GRANULES GRAN IN Market Cap
More informationGRANULES INDIA LIMITED
Independent Equity Research PHARMACEUTICALS BSE Scrip Code: 532482 CMP Rs. 70.35 1 14 Feb 2012 Vertically intergrated and present across the pharma manufacturing value chain Granules India Limited (Granules)
More informationGHCL Ltd. 19 th September, 2016 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY GHCL Ltd. 19 th September, 2016 BUY CMP (BSE) Rs.253.00 Target Price Rs.310.00 BSE Code 500171 Market Cap (Rs Cr.) 2530.49 52 Week High/Low
More informationLONG TERM SUBSCRIBE. IPO Report HINDUSTAN AERONAUTICS LTD. IPO Details. Research Analyst : Astha Jain
IPO Report HINDUSTAN AERONAUTICS LTD LONG TERM SUBSCRIBE IPO Details Issue Date 16 th Mar-20 th Mar 2018 Price Band Bid Lot Face Value Listing Offer For Sale Fresh Issue ---- Pre Issue Eq Shares Post Issue
More informationMeghmani Organics Ltd 24th Aug 2017 BUY
BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY MERCHANT BANKING Meghmani Organics Ltd 24th Aug 2017 BUY CMP Rs. 72.65 Target Price Rs 95.00 BSE Code 532865 NSE Code MEGH Market Cap (Rs crore) Rs. 1847.49
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationGRANULES INDIA STRATEGIC SHIFT
GRANULES INDIA STRATEGIC SHIFT 4 Recommendation BUY STRATEGIC SHIFT CMP (19 Jan 2015) Rs 830 Target Price Rs 1128 Sector Stock Details Pharmaceuticals BSE Code 532482 NSE Code Bloomberg Code GRANULES GRAN
More informationSUBSCRIBE. IPO Report BHARAT DYNAMICS LTD. IPO Details. Research Analyst : Astha Jain
IPO Report BHARAT DYNAMICS LTD SUBSCRIBE IPO Details Issue Date 13 th Mar-15 th Mar 2018 Price Band 413-428/Share* Bid Lot 35 & in multiplethereof Face Value Rs 10/Share Listing BSE, NSE Offer For Sale
More informationLARGE CAP & 1,970 BSE
Batlivala & Karani RESULT UPDATE LARGE CAP Share Data Reuters code DIVI.BO Bloomberg code DIVI IN Market cap. (US$ mn) 4,97 6M avg. daily turnover (US$ mn) 4.7 Issued shares (mn) 133 Target price (Rs)
More informationAVOID. IPO Report GARDEN REACH SHIPBUILDERS & ENGINEERS LTD. IPO Details. Research Analyst : Astha Jain
IPO Report AVOID IPO Details Issue Date 24 th Sept-26 th Sept 2018 Price Band 115-118/Share * Bid Lot 120 & in multiplethereof Face Value Rs 10/Share Listing BSE, NSE Offer For Sale 29,210,760 Eq Shares
More informationGMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months
2QFY2019 Result Update Industrial Machinery October 26, 2018 GMM Pfaudler Limited Performance Update Standalone (` cr) Q2FY19 Q2FY18 % yoy Q1FY19 % qoq Net sales 99.2 93.2 29.8% 76.4 6.4% EBITDA 16.0 15.3
More informationParag Milk Foods BUY. Performance Update CMP. `324 Target Price `410. 1QFY2019 Result Update Dairy Products. Investment Period 12 Months
1QFY2019 Result Update Dairy Products August 8, 2018 Parag Milk Foods Performance Update Y/E March (` cr) Q1FY19 Q1FY18 % yoy Q4FY18 % qoq Net sales 549 413 32.9 518 5.9 EBITDA 60 29 103% 55 8.4% EBITDA
More informationParag Milk Foods BUY. Performance Update CMP. `256 Target Price `330. 2QFY2019 Result Update Dairy Products. Investment Period 12 Months
2QFY2019 Result Update Dairy Products November 6, 2018 Parag Milk Foods Performance Update Y/E March (` cr) Q2FY19 Q2FY18 % yoy Q1FY19 % qoq Net sales 573 505 13.7% 549 4.4% EBITDA 58 50 16.3% 60-2.7%
More informationMarket Snap 02 nd June 2018
Weekly ary Market Snap 02 nd June 2018 BROKING INVESTMENT BANKING l RESEARCH DISTRIBUTION l DEPOSITORY Index Previous Close Open High Low Close Change Change (%) Sensex 34924.87 35074.32 35438.22 34735.11
More informationCCL Products BUY. Performance Update. CMP Target Price `278 `360. 3QFY2018 Result Update Coffee. Historical share price chart.
Feb-15 May-15 Aug-15 Oct-15 Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 3QFY2018 Result Update Coffee February 5, 2018 CCL Products Performance Update Y/E March (` cr) Q3FY18 Q3FY17
More informationBlue Star Ltd BUY. Performance Update. CMP Target Price `754 `867. 4QFY2018 Result Update Cons. Durable. 3-year price chart.
May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 Feb-18 May-18 4QFY2018 Result Update Cons. Durable May 16, 2018 Blue Star Ltd Performance Update 4QFY18 4QFY17 % chg. (yoy)
More informationGranules India Ltd Pharmaceuticals BUY RETAIL EQUITY RESEARCH. Higher API and FD sales drove the numbers. Revenue growth led by API and FD sales...
Q2 FY19 RESULT UPDATE RETAIL EQUITY RESEARCH Granules India Ltd Pharmaceuticals BSE CODE: 532482 NSE CODE: GRANULES Bloomberg CODE: GRAN:IN SENSEX: 34,432 BUY Rating as per mid cap 12months investment
More informationBloomberg Code: ATA IN
Auto OEM: 3-Wheelers Atul Feb Auto 03, 2015 Ltd India Research Stock Broking Bloomberg Code: ATA IN Stable quarter led by surge in exports volumes (TP revised ) : Operating revenue, EBITDA and PAT grew
More informationAhluwalia Contracts (India)
May-14 Jul-14 Aug-14 Sep-14 Oct-14 Dec-14 Jan-15 Feb-15 Apr-15 May-15 India Research Infrastructure May 22, 215 QUARTERLY REVIEW Bloomberg: AHLU IN Reuters: AHLU.BO BUY Better performance ahead ACIL posted
More informationStrong Margins, Robust Profitability Quarter I Results, FY EBITDA up 44%, Net profit up 43%
Strong Margins, Robust Profitability Quarter I Results, FY 2013 14 EBITDA up 44%, Net profit up 43% Mumbai, Aug 7, 2013: Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30
More informationApollo Hospitals Enterprise Ltd.
Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17. Volume No.. I Issue No. 154 Apollo Hospitals Enterprise Ltd. December 19, 2017 BSE Code: 508869 NSE Code: APOLLOHOSP
More informationAurobindo Pharma Ltd.
. Volume No.. I Issue No. 165 Aurobindo Pharma Ltd. March 12, 2018 BSE Code: 524804 NSE Code: AUROPHARMA Reuters Code: ARBN.NS Bloomberg Code: ARBP:IN Aurobindo Pharma Ltd (Auro) is one of the largest
More informationPress Release. Consolidated Financial & Performance Highlights (Pharma & Biotech)
Press Release Strides Shasun announces Q1 FY17 results Q1 FY17 Pharma Revenues* at INR 8,699 Mn, Growth of 43% YoY, Pharma EBITDA at INR 1,451 Mn, Growth of 57% YoY Bengaluru, August 17, 2016: Strides
More informationALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
More informationSanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 3QCY2017 Result Update Pharmaceutical. Investment Period 12 months
3QCY2017 Result Update Pharmaceutical November 20, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 3QCY2017 2QCY2017 % chg (qoq) 3QCY2016 % chg (yoy) Net sales Other income Operating profit 627
More informationSanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 2QCY2017 Result Update Pharmaceutical. 3-year price chart.
2QCY2017 Result Update Pharmaceutical August 28, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 2QCY2017 1QCY2017 % chg (qoq) 2QCY2016 % chg (yoy) Net sales Other income Operating profit 556
More informationPhillips Carbon Black Ltd
4 Recommendation BOOK PROFITS Pain not yet over CMP (09/02/2015)* Rs. 131 Phillips Carbon Black (PCB) reported results in line with expectations; with EBITDA margins at 10.0% vs 9.3% in Q2FY15. The company
More informationMarket Snap 26 th May 2018
Weekly ary Market Snap 26 th May 2018 BROKING INVESTMENT BANKING l RESEARCH DISTRIBUTION l DEPOSITORY Index Previous Close Open High Low Close Change Change (%) Sensex 34848.30 34873.16 35017.93 34302.89
More informationLupin 1QFY2018 Result Update
Jul-12 Nov-12 Mar-13 Jul-13 Nov-13 Mar-14 Jul-14 Nov-14 Mar-15 Jul-15 Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 1QFY2018 Result Update Pharmaceutical August 07, 2017 Lupin Performance Highlights Y/E March
More informationNRB BEARINGS LTD CMP. 16 July 2018 INR 164. Target Price. Initiating Coverage (BUY) INR 200
16 July 2018 NRB BEARINGS LTD CMP INR 164 Initiating Coverage (BUY) Target Price INR 200 Stock Details Industry Industrial Machinery Bloomberg Code NRBBR:IN BSE Code 530367 Face Value (Rs.) 2.00 Market
More informationCadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514
3QFY15 Result Update Institutional Equities Cadila Healthcare 11 February 2015 Reuters: CADI.BO; Bloomberg: CDH IN Stable Performance Cadila Healthcare s (CHL) 3QFY15 earnings were in line with our expectations
More informationTata Steel NEUTRAL. Performance Highlights CMP. `226 Target Price - 2QFY2016 Result Update Steel. Investment Period - 3-year price chart
2QFY2016 Result Update Steel November 6, 2015 Tata Steel Performance Highlights Standalone (` cr) 2QFY16 2QFY15 yoy % 1QFY16 qoq % Net revenue 9,531 10,785 (11.6) 9,094 4.8 EBITDA 1,862 3,094 (39.8) 1,689
More informationSHRIRAM TRANSPORT FINANCE COMPANY LTD
27 June 2017 SHRIRAM TRANSPORT FINANCE COMPANY LTD CMP INR 975 Initiating Coverage (BUY) Target Price INR 1225 Stock Details Industry Finance (including NBFCs) Bloomberg Code SHTF:IN BSE Code 511218 Face
More informationITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months
3QFY2017 Result Update FMCG January 30, 2017 ITC Performance Highlights Quarterly result (Standalone) (` cr) 3QFY17 3QFY16 % yoy 2QFY17 %qoq Revenue 9,248 8,867 4.3 9,661 (4.3) EBITDA 3,546 3,475 2.1 3,630
More informationVisaka Industries Ltd
Company Update Superior Product Mix & New Age Markets to Aid Growth New investments to aid growth: Visaka continues to give a good set of numbers. YoY EPS grew at 142% aided by a revenue growth of 1.5%
More informationKey Highlights. YoY (% change) Q1FY10. QoQ % Particulars 2Q FY10 2Q FY09 Realizations per tone 31,899 53,436-40% 30,462 5% Source: Company
29th October, 2009 Key Data INR CMP 743 Target Price 646 Earlier target price 481 Bloomberg Code JSTL IN Reuters Code JSTL.BO BSE Code 500228 NSE Code JSWSTEEL Face Value (INR) 10 Market Cap (INR bn) 142
More informationPSP Projects Ltd. 1 P a g e. Subscribe with Long Recommendation. Term View BACKGROUND
Subscribe with Long Recommendation Term View BACKGROUND Price Band Rs. 205 Rs. 210 (PSP) is a multidisciplinary construction company Bidding Date 17 th Sep - 19 th May 2017 Book Running Lead Manager Registrar
More informationAlembic BUY. Performance Highlights. Target Price. 1QFY2011 Result Update Pharmaceutical. Investment Period 12 months
1QFY2011 Result Update Pharmaceutical August 2, 2010 Alembic Performance Highlights Y/E March (Rs cr) 1QFY2011 4QFY2010 % chg (qoq) 1QFY2010 % chg (yoy) Net Sales 279 267 4.6 291 (4.0) Other Income 1 1
More informationSanofi India NEUTRAL. Performance Highlights. CMP `4,301 Target Price - 4QCY2016 Result Update Pharmaceutical. Investment Period - 3-year price chart
4QCY2016 Result Update Pharmaceutical March 10, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 4QCY2016 3QCY2016 % chg (qoq) 4QCY2015 % chg (yoy) Net sales 552 583 (5.3) 522 5.6 Other income
More informationSymphony Ltd. RESULT UPDATE 31st October 2017
. RESULT UPDATE 31st October 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October 2017. CMP INR 1,465 Target INR 1,700 Potential
More informationQuarterly results (YE Mar) 2QFY14 2QFY15 % yoy H1FY14 H1FY15 % yoy
India I Equities Healthcare Result Update 3 November 2014 Granules India Strong performance, margin improvement to sustain; Buy Rating: Buy Target Price: `1,185 Share Price: `807 Key takeaways Strong quarter.
More informationQuick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.
Ltd. Creating value through paper Limited (RPL) manufactures writing paper, printing paper and Kraft paper. The company's white writing and printing paper is used in making notebooks and writing material,
More informationGarware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months
2QFY217 Result Update Textile November 16, 216 Garware Wall Ropes Performance Highlights Quarterly Data (`cr) 2QFY17 2QFY16 % yoy 1QFY17 % qoq Revenue 232 214 8.5 225 3.3 EBITDA 4 26 5.9 31 29.4 Margin
More informationJenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited Date: 3 rd February, 2016 Stock Performance Details Shareholding Details October 2015 Current Price : ` 418.0^ Face Value : ` 10 per share 52 wk High / Low : ` 542.8 /
More informationFineotex Chemical Ltd
Company Update Decent Performance under Macroeconomic Pressure; Business Traction to Continue: Fineotex Chemical recorded decent set of result as consolidated sales grew by 1.1% YoY (largely in line) to
More information3QFY09 revenues in line but adjusted margins beat KIE. No changes in estimates for FY E
India Daily Summary - January 29, 2009 LUPIN January 29, 2009 Pharmaceuticals LUPN.BO, Rs562 Rating Sector coverage view Target Price (Rs) BUY Attractive 950 52W High -Low (Rs) 782-438 Market Cap (Rs bn)
More informationSQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E
Company Update Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E EBITDA Margins recovered by 618 bps QoQ: The company has witnessed many challenges over the year FY17 starting
More informationBulls maintain their grip for the third week in a row
Weekly Commentary Market Snap 17 th November 2018 www.hemsecurities.com www.hemsecurities.com BROKING INVESTMENT BANKING RESEARCH DISTRIBUTION DEPOSITORY Index Previous Close Open High Low Close Change
More informationHindustan Media Ventures
2QFY216 Result Update Media October 27, 215 Hindustan Media Ventures Performance Highlights Quarterly Data (` cr) 2QFY16 2QFY15 % yoy 1QFY15 % qoq Revenue 227 2 13.7 224 1.4 EBITDA 52 39 33.1 55 (4.5)
More informationKPIT Cummins Infosystems Ltd
4 Recommendation HOLD Q1FY13 results above expectations; onsite volume growth of 7%, pricing stable. CMP Target Price Sector Stock Details Rs.126 Rs.137 IT Software products BSE Code 532400 NSE Code Bloomberg
More informationLarsen & Toubro Ltd.
Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Volume No.. III Issue No. 163. Larsen & Toubro Ltd. February 26, 2018 BSE Code: 500510 NSE Code: LT Reuters Code:
More informationGraphite India BUY. Performance Highlights CMP. `93 Target Price `124. 4QFY2012 Result Update Capital Goods. Investment Period 12 Months
4QFY2012 Result Update Capital Goods May 11, 2012 Graphite India Performance Highlights Y/E March (` cr) 4QFY2012 3QFY2012 % chg (qoq) 4QFY2011 % chg (yoy) Net sales 452 437 3.5 304 48.6 EBITDA 83 90 (7.7)
More informationFY2017 FY2018E FY2019E
Jul-12 Dec-12 May-13 Oct-13 Mar-14 Aug-14 Jan-15 Jun-15 Nov-15 Apr-16 Sep-16 Feb-17 Jul-17 2QFY2018 Result Update Pharmaceutical November 20, 2017 Lupin Performance Highlights Y/E March (`cr) 2QFY2018
More informationSpiceJet ACCUMULATE. Performance Highlights. 4QFY2010 Result Update I Aviation
4QFY2010 Result Update I Aviation June 3, 2010 SpiceJet Performance Highlights For 4QFY2010, SpiceJet s Top-line grew 34.3% yoy but fell 12.8% qoq to Rs560cr, slightly lower than our estimate of Rs590cr.
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/ Apr/15 May/ Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/ Dec/15 Parnax Lab Limited CMP: 53.90 January 08, 2016 Stock Details BSE code 506128 BSE ID PARNAXLAB Face value ( ) 10 No of shares
More informationJ.B. Chemicals & Pharmaceuticals Ltd.
Oct-16 Nov-16 Nov-16 Dec-16 Jan-17 Jan-17 Feb-17 Mar-17 Apr-17 Apr-17 May-17 Jun-17 Jun-17 Jul-17 Aug-17 Aug-17 Sep-17 Oct-17. Volume No.. I Issue No. 146 J.B. Chemicals & Pharmaceuticals Ltd. October
More informationPrabhat Dairy Ltd. RESULT UPDATE 8th June, 2018
RESULT UPDATE 8 th June, 2018 Sep-15 Jan-16 May-16 Sep-16 Jan-17 May-17 Sep-17 Jan-18 May-18 India Equity Institutional Research II Result Update - Q4FY18 II 8 th June, 2018 2 Under Expansion Mode CMP
More informationLupin BUY. Performance Highlights. CMP `1,493 Target Price `1,809. 2QFY2017 Result Update Pharmaceutical. 3-year price chart
2QFY2017 Result Update Pharmaceutical November 11, 2016 Lupin Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg qoq 2QFY2016 % chg yoy Net sales 4,212 4,316 (2.4) 3,193 31.9 Other income
More informationCoal India ACCUMULATE. Performance Highlights CMP. `338 Target Price `380. Outlook and valuation. 2QFY2016 Result Update Mining
Coal India Performance Highlights (` cr) % yoy % qoq Net Sales 16,958 15,678 8.2 18,956 (1.5) EBITDA 3,8 2,556 17.7 4,944 (39.2) % margin 17.2 15.8 139bp 25.3 (813bp) Net Profit 2,519 2,188 15.2 3,787
More informationJK Paper Ltd 16/02/2018 BUY
BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY MERCHANT BANKING JK Paper Ltd 16/02/2018 BUY CMP Rs 137.55 Target Price Rs 180.00 BSE Code 532162 NSE Code JKPAPER Market Cap (Rs crore) Rs.2414.00 52
More informationAurobindo Pharma BUY. Performance Highlights CMP. `109 Target Price `156. 1QFY2013 Result Update Pharmaceutical. Investment Period 12 months
1QFY2013 Result Update Pharmaceutical August 8, 2012 Aurobindo Pharma Performance Highlights Y/E march (` cr) 1QFY2013 4QFY2012 % chg (qoq) 1QFY2012 % chg (yoy) Net sales 1197 1171 2.3 1065 12.4 Other
More informationRobust results, TLT margins improved profitability.
Power Transmission Equipment Result Update Skipper Ltd BUY Robust results, TLT margins improved profitability. Institutional Research Nifty: 8,4; Sensex: 26,553 CMP (Rs) 153 Target (Rs) 17 Key Stock Data
More informationCummins India Ltd Bloomberg Code: KKC IN
Company Update Margins Under Pressure; Domestic Recovery Underway Half-yearly revenue was flat; margins were under pressure: Cummins India revenue, EBITDA and PAT for H1FY17 reached to Rs.24,784mn, Rs.4,649mn
More informationVolume No. I Issue No. 22 May 23, 2014 FINANCIAL SUMMARY
For private circulation only Volume No. I Issue No. 22 Maruti Suzuki India Smooth road ahead Price: Rs 2386 Target Price: Rs 2800 Sensex: 24,693 Nifty: 7,367 FINANCIAL SUMMARY SALES OPM (%) OP OTHER INC.
More informationHavells India. Q1FY18 Result Update Strong Sales growth; Margins decline. Sector: Consumer Durable CMP: ` 467. Recommendation: BUY
Havells India Q1FY18 Result Update Strong Sales growth; Margins decline Sector: Consumer Durable CMP: ` 467 Recommendation: BUY Market statistics Current stock price (`) 467 Shares O/S (cr.) 62.5 Mcap
More informationColgate-Palmolive ACCUMULATE. Performance Highlights. 4QFY2010 Result Update I FMCG
4QFY2010 Result Update I FMCG May 27, 2010 Colgate-Palmolive Performance Highlights ACCUMULATE CMP Target Price Rs715 Rs752 We highlight the fact that the current quarter results are not comparable yoy/qoq,
More informationMarket Snap 12 th May 2018
Weekly ary Market Snap 12 th May 2018 BROKING INVESTMENT BANKING l RESEARCH DISTRIBUTION l DEPOSITORY Index Previous Close Open High Low Close Change Change (%) Sensex 34915.38 34983.59 35596.15 34977.74
More informationMahindra & Mahindra Ltd.
May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 Feb-18 4QFY2018 Result Update Automobile May 30, 2018 Mahindra & Mahindra Ltd. Performance Update Y/E March (` cr) 4QFY18 4QFY17
More informationResult Update. Diversified Voltas Ltd BUY. Target Price Rs 197. Key Data. Key Highlights. One Year Price / Volume Chart
Result Update 29 th January 2010 Diversified BUY CMP Rs 159 Target Price Rs 197 Key Data Face Value (Rs) 1 Market Cap (Rs Crs) 5201.75 Total O/s Shares (Crs) 33.0 Free Float (%) 72.3 52 week H/L (Rs) 190/31
More informationBlue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.
Aug-15 Oct-15 Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 Jan-17 Apr-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 Jul-18 1QFY2019 Result Update Cons. Durable August 10, 2018 Blue Star Ltd Performance
More informationGeneral Insurance Corporation of India Ltd.
General Insurance Corporation of India Ltd. Reco: Subscribe 10 th October, 2017 Fresh Issue of 1.72 Crore Equity Shares & Offer For Sale of 10.75 Crore Equity Shares of FV Rs 5/- each (Rs. 11,372 Crs)
More informationResult Analysis. Recommendation CMP (09/02/2010) Rs. 212
Recommendation BUY CMP (09/02/2010) Rs. 212 Sector Stock Details BSE Code NSE Code Bloomberg Market Cap (Rs. cr) Free Float (%) 52- wk HI/Lo Avg. volume BSE (Quarterly) Face Value Dividend (FY09) Shares
More informationCompany Overview. Financial Performance
Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 Jan/16 Feb/16 Mar/16 Monarch Networth Capital Limited CMP: 26.00 March 23, 2016 Stock Details BSE code 511551 BSE ID MONARCH Face value (
More informationMaruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart
Jul-15 Sep-15 Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 1QFY2019 Result Update Automobile July 27, 2018 Maruti Suzuki India Performance
More informationTata Steel BUY. Performance Highlights. 3QFY2010 Result Update I Steel
3QFY2010 Result Update I Steel January 29, 2010 Tata Steel Performance Highlights Tata Steel s standalone 3QFY2010 net revenue increased by 33.2% yoy and 12.0% qoq to Rs6,307.5cr, ahead of our estimates
More informationULTRAMARINE & PIGMENTS LTD
02 December 2016 ULTRAMARINE & PIGMENTS LTD CMP INR 170 Initiating Coverage (BUY) Target Price INR 226 Stock Details Industry SPECIALTY CHEMICALS Bloomberg Code UMP:IN BSE Code 506685 Face Value (Rs.)
More informationProcter & Gamble Hygiene & Health Care
3QFY216 Result Update FMCG May 6, 216 Procter & Gamble Hygiene & Health Care Performance Highlights Quarterly Data (` cr) 3QFY16 3QFY15 % yoy 2QFY16 % qoq Revenue 614 555 1.5 714 (14.) EBITDA 133 123 8.5
More information